Brief: ProQR Therapeutics NV - Receives CTA Authorization for Phase 1 Study of AX-0810
20/10/2025 13:22
Oct 20 (Reuters) - ProQR Therapeutics NV PRQR.O: PROQR THERAPEUTICS NV - RECEIVES CTA AUTHORIZATION FOR PHASE 1 STUDY OF AX-0810 Source text: ID:nGNX1gHt42 Further company coverage: PRQR.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on ProQR Therapeutics NV
See all newsProQR Therapeutics NV reports results for the quarter ended June 30 - Earnings Summary
ProQR Q2 revenue more than doubles
Brief: ProQR Therapeutics Q2 EPS EUR -0.08
ProQR Therapeutics NV expected to post a loss of 11 cents a share - Earnings Preview
ProQR Therapeutics NV expected to post a loss of 11 cents a share - Earnings Preview